Scott E. Woodman, M.D., Ph.D.

Peer-Reviewed Articles

1. Cabanillas, ME, Dadu, R, Ferrarotto, R, Gule-Monroe, MK, Liu, S, Fellman, B, Williams, MD, Zafereo, M, Wang, RJ, Lu, C, Ning, M, McKinley, BA, Woodman, SE, Duose, D, Gunn, GB, Busaidy, NL. Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma. JAMA Oncology 10(12):1672-1680, 2024. e-Pub 2024. PMID: 39446377.
2. Wang, X, Zhao, L, Song, X, Wu, X, Krishnamurthy, S, Semba, T, Shao, SH, Knafl, M, Coffer, LW, Alexander, A, Vines, A, Bopparaju, S, Woodward, W, Chu, RA, Zhang, J, Yam, C, Loo, LW, Nasrazadani, A, Huong, LP, Woodman, SE, Futreal, A, Zhang, S, Zhang, Q, Xu, M, Wistuba, II, Wang, W, Virani, S, Sun, B, Subramanya, S, Song, X, Song, P, Shaw, KR, Prabhakaran, S, Marques-Piubelli, ML, Mohammad, MM, Meric-Bernstam, F, Mendoza, MT, Mallampati, S, Lu, W, Little, L, Lang, W, Kinyua, W, Khanduri, I, Jiang, M, Jacob, J, Jackson, S, Gite, S, Garcia-Prieto, C, Arrechedera, C, Tripathy, D. Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancer. npj Precision Oncology 8(1), 2024. e-Pub 2024. PMID: 39558017.
3. Hornstein NJ, Zeineddine MA, Gunes BB, Pellatt AJ, Knafl M, Zhu H, Willett AF, Yousef A, Liu S, Sun R, Futreal A, Woodman SE, Taggart MW, Overman MJ, Halperin DM, Raghav KP, Shen JP. Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma. Cancer Res Commun 4(5):1363-1368, 2024. e-Pub 2024. PMID: 38709066.
4. de Sousa LG, Liu S, Bhosale P, Altan M, Darbonne W, Schulze K, Dervin S, Yun C, Mahvash A, Verma A, Futreal A, Gite S, Cuentas EP, Cho WC, Wistuba I, Yao JC, Woodman SE, Halperin DM, Ferrarotto R. Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study. Oral Oncol 151:106747, 2024. e-Pub 2024. PMID: 38460288.
5. Qin K, Wang K, Li S, Hong L, Padmakumar P, Waree R, Hubert SM, Le X, Vokes N, Rai K, Vaporciyan A, Gibbons DL, Heymach JV, Lee JJ, Woodman SE, Chung C, Jaffray DA, Altan M, Lou Y, Zhang J. Clinical Benefit from Docetaxel +/- Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy. Cancers (Basel) 16(5), 2024. e-Pub 2024. PMID: 38473297.
6. Noh, S, Bertini, CD, Mira-Avendano, I, Kaous, M, Patel, B, Faiz, S, Shannon, VR, Balachandran, D, Bashoura, L, Adachi, R, Evans, S, Dickey, BF, Wu, CC, Shroff, G, Manzano, JM, Granwehr, BP, Holloway, S, Dickson, KB, Mohammed, AD, Muthu, M, Song, H, Aroe, A, Aloia, TA, Lee Andrews, II, Badami, KK, Beird, H, Brock, K, Cata, JP, Dabaja, BS, Draetta, G, French, KE, Godoy, M, Hutcheson, KA, Jaffray, D, John, TM, Lee, JJ, Litton, J, McEnery, KW, Musunuru, TN, Nates, JL, Palaskas, NL, Ravi, V, Scheet, PA, Shete, S, Subbiah, IM, Tawbi, H, Woodman, SE, Chung, C, Khawaja, F, Sheshadri, A. Interstitial lung abnormalities after hospitalization for COVID-19 in patients with cancer. Cancer medicine 12(17):17753-17765, 2023. e-Pub 2023. PMID: 37592894.
7. Reddy DR, Cuenca JA, Botdorf J, Muthu M, Hanmandlu A, Wegner R, Crommett J, Gutierrez C, Rathi N, Sajith B, Knafl M, Abbas HA, Woodman SE, Nates JL, Collaborators DT. Clinical Characteristics and Cause of Death Among Hospitalized Decedents With Cancer and COVID-19. Mayo Clin Proc 98(3):451-457, 2023. e-Pub 2023. PMID: 36868753.
8. Cata JP, Hu J, Feng L, Chung C, Woodman SE, Meyer LA. Association between COVID-19 and Postoperative Neurological Complications and Antipsychotic Medication Use after Cancer Surgery: A Retrospective Study. J Pers Med 13(2), 2023. e-Pub 2023. PMID: 36836508.
9. Hahn AW, Menk AV, Rivadeneira DB, Augustin RC, Xu M, Li J, Wu X, Mishra AK, Gide TN, Quek C, Zang Y, Spencer CN, Menzies AM, Daniel CR, Hudgens CW, Nowicki T, Haydu LE, Khan MAW, Gopalakrishnan V, Burton EM, Malke J, Simon JM, Bernatchez C, Putluri N, Woodman SE, Vashisht Gopal YN, Guerrieri R, Fischer GM, Wang J, Wani KM, Thompson JF, Lee JE, Hwu P, Ajami N, Gershenwald JE, Long GV, Scolyer RA, Tetzlaff MT, Lazar AJ, Schadendorf D, Wargo JA, Kirkwood JM, DeBerardinis RJ, Liang H, Futreal A, Zhang J, Wilmott JS, Peng W, Davies MA, Delgoffe GM, Najjar YG, McQuade JL. Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma. Clin Cancer Res 29(1):154-164, 2023. e-Pub 2023. PMID: 36166093.
10. Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA. Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature 613(7945):E3, 2023. e-Pub 2023. PMID: 36627494.
11. Aminu M, Yadav D, Hong L, Young E, Edelkamp P, Saad M, Salehjahromi M, Chen P, Sujit SJ, Chen MM, Sabloff B, Gladish G, de Groot PM, Godoy MCB, Cascone T, Vokes NI, Zhang J, Brock KK, Daver N, Woodman SE, Tawbi HA, Sheshadri A, Lee JJ, Jaffray D, Team D, Wu CC, Chung C, Wu J. Habitat Imaging Biomarkers for Diagnosis and Prognosis in Cancer Patients Infected with COVID-19. Cancers (Basel) 15(1), 2022. e-Pub 2022. PMID: 36612278.
12. Andrews MC, Oba J, Wu CJ, Zhu H, Karpinets T, Creasy CA, Forget MA, Yu X, Song X, Mao X, Robertson AG, Romano G, Li P, Burton EM, Lu Y, Sloane RS, Wani KM, Rai K, Lazar AJ, Haydu LE, Bustos MA, Shen J, Chen Y, Morgan MB, Wargo JA, Kwong LN, Haymaker CL, Grimm EA, Hwu P, Hoon DSB, Zhang J, Gershenwald JE, Davies MA, Futreal PA, Bernatchez C, Woodman SE. Multi-modal molecular programs regulate melanoma cell state. Nat Commun 13(1):4000, 2022. e-Pub 2022. PMID: 35810190.
13. Halperin DM, Liu S, Dasari A, Fogelman D, Bhosale P, Mahvash A, Estrella JS, Rubin L, Morani AC, Knafl M, Overeem TA, Fu SC, Solis LM, Parra Cuentas E, Verma A, Chen HL, Gite S, Subashchandrabose P, Dervin S, Schulze K, Darbonne WC, Yun C, Wistuba II, Futreal PA, Woodman SE, Yao JC. Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial. JAMA Oncol 8(6):904-909, 2022. e-Pub 2022. PMID: 35389428.
14. Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature 606(7915):797-803, 2022. e-Pub 2022. PMID: 35705814.
15. Spencer CN, McQuade JL, Gopalakrishnan V, McCulloch JA, Vetizou M, Cogdill AP, Khan MAW, Zhang X, White MG, Peterson CB, Wong MC, Morad G, Rodgers T, Badger JH, Helmink BA, Andrews MC, Rodrigues RR, Morgun A, Kim YS, Roszik J, Hoffman KL, Zheng J, Zhou Y, Medik YB, Kahn LM, Johnson S, Hudgens CW, Wani K, Gaudreau PO, Harris AL, Jamal MA, Baruch EN, Perez-Guijarro E, Day CP, Merlino G, Pazdrak B, Lochmann BS, Szczepaniak-Sloane RA, Arora R, Anderson J, Zobniw CM, Posada E, Sirmans E, Simon J, Haydu LE, Burton EM, Wang L, Dang M, Clise-Dwyer K, Schneider S, Chapman T, Anang NAS, Duncan S, Toker J, Malke JC, Glitza IC, Amaria RN, Tawbi HA, Diab A, Wong MK, Patel SP, Woodman SE, Davies MA, Ross MI, Gershenwald JE, Lee JE, Hwu P, Jensen V, Samuels Y, Straussman R, Ajami NJ, Nelson KC, Nezi L, Petrosino JF, Futreal PA, Lazar AJ, Hu J, Jenq RR, Tetzlaff MT, Yan Y, Garrett WS, Huttenhower C, Sharma P, Watowich SS, Allison JP, Cohen L, Trinchieri G, Daniel CR, Wargo JA. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science 374(6575):1632-1640, 2021. e-Pub 2021. PMID: 34941392.
16. Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov 11(11):2738-2747, 2021. e-Pub 2021. PMID: 34261675.
17. Sloane RAS, White MG, Witt RG, Banerjee A, Davies MA, Han G, Burton E, Ajami N, Simon JM, Bernatchez C, Haydu LE, Tawbi HA, Gershenwald JE, Keung E, Ross M, McQuade J, Amaria RN, Wani K, Lazar AJ, Woodman SE, Wang L, Andrews MC, Wargo JA. Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. Cancers (Basel) 13(21), 2021. e-Pub 2021. PMID: 34771465.
18. Andrews MC, Duong CPM, Gopalakrishnan V, Iebba V, Chen WS, Derosa L, Khan MAW, Cogdill AP, White MG, Wong MC, Ferrere G, Fluckiger A, Roberti MP, Opolon P, Alou MT, Yonekura S, Roh W, Spencer CN, Curbelo IF, Vence L, Reuben A, Johnson S, Arora R, Morad G, Lastrapes M, Baruch EN, Little L, Gumbs C, Cooper ZA, Prieto PA, Wani K, Lazar AJ, Tetzlaff MT, Hudgens CW, Callahan MK, Adamow M, Postow MA, Ariyan CE, Gaudreau PO, Nezi L, Raoult D, Mihalcioiu C, Elkrief A, Pezo RC, Haydu LE, Simon JM, Tawbi HA, McQuade J, Hwu P, Hwu WJ, Amaria RN, Burton EM, Woodman SE, Watowich S, Diab A, Patel SP, Glitza IC, Wong MK, Zhao L, Zhang J, Ajami NJ, Petrosino J, Jenq RR, Davies MA, Gershenwald JE, Futreal PA, Sharma P, Allison JP, Routy B, Zitvogel L, Wargo JA. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med 27(8):1432-1441, 2021. e-Pub 2021. PMID: 34239137.
19. Terranova CJ, Tang M, Maitituoheti M, Raman AT, Ghosh AK, Schulz J, Amin SB, Orouji E, Tomczak K, Sarkar S, Oba J, Creasy C, Wu CJ, Khan S, Lazcano R, Wani K, Singh A, Barrodia P, Zhao D, Chen K, Haydu LE, Wang WL, Lazar AJ, Woodman SE, Bernatchez C, Rai K. Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy. Cell Rep 36(3):109410, 2021. e-Pub 2021. PMID: 34289358.
20. Kothari AN, Trans AT, Caudle AS, Clemens MW, Katz MHG, Woodman SE, Chang GJ. Universal preoperative SARS-CoV-2 testing can facilitate safe surgical treatment during local COVID-19 surges. Br J Surg 108(1):e24-e26, 2021. e-Pub 2021. PMID: 33640925.
21. White MG, Szczepaniak Sloane R, Witt RG, Reuben A, Gaudreau PO, Andrews MC, Feng N, Johnson S, Class CA, Bristow C, Wani K, Hudgens C, Nezi L, Manzo T, De Macedo MP, Hu J, Davis R, Jiang H, Prieto P, Burton E, Hwu P, Tawbi H, Gershenwald J, Lazar AJ, Tetzlaff MT, Overwijk W, Woodman SE, Cooper ZA, Marszalek JR, Davies MA, Heffernan TP, Wargo JA. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma. Oncoimmunology 10(1):1992880, 2021. e-Pub 2021. PMID: 34777916.
22. Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, LeBleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R, Woodman SE, Keung EZ, Gaudreau PO, Reuben A, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong S, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, Blank CU, Schumacher TN, Butterfield LH, Zelazowska MA, McBride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Sautès-Fridman C, Hacohen N, Rezvani K, Sharma P, Tetzlaff MT, Wang L, Wargo JA. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577(7791):549-555, 2020. e-Pub 2020. PMID: 31942075.
23. Chattopadhyay C, Oba J, Roszik J, Marszalek JR, Chen K, Qi Y, Eterovic K, Robertson AG, Burks JK, McCannel TA, Grimm EA, Woodman SE. Elevated Endogenous SDHA Drives Pathological Metabolism in Highly Metastatic Uveal Melanoma. Invest Ophthalmol Vis Sci 60(13):4187-4195, 2019. e-Pub 2019. PMID: 31596927.
24. Zeng J, Johnson A, Shufean MA, Kahle M, Yang D, Woodman SE, Vu T, Moorthy S, Holla V, Meric-Bernstam F. Operationalization of Next-Generation Sequencing and Decision Support for Precision Oncology. JCO Clin Cancer Inform 3:1-12, 2019. e-Pub 2019. PMID: 31550176.
25. Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman SE, Hwu WJ, Hwu P, Wang Y, Diab A. Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer 7(1):107, 2019. e-Pub 2019. PMID: 30995944.
26. McKean M, Oba J, Ma J, Roth KG, Wang WL, Macedo MP, Carapeto FCL, Haydu LE, Siroy AE, Vo P, Hong DS, Eterovic AK, Patel KP, Bassett RL, Grimm EA, Lazar AJ, Woodman SE. Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma. J Invest Dermatol 139(3):728-731, 2019. e-Pub 2019. PMID: 30798855.
27. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman SE, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24(11):1649-1654, 2018. e-Pub 2018. PMID: 30297909.
28. Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman SE, Hwu WJ, Hwu P, Wang Y, Diab A. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer 6(1):103, 2018. e-Pub 2018. PMID: 30305177.
29. Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C. Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome. Clin Cancer Res 24(18):4416-4428, 2018. e-Pub 2018. PMID: 29848573.
30. Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, Villalobos PA, Cascone T, Liu X, Tan L, Lorenzi PL, Huang A, Zhao Q, Peng D, Fradette JJ, Peng DH, Ungewiss C, Roybal J, Tong P, Oba J, Skoulidis F, Peng W, Carter BW, Gay CM, Fan Y, Class CA, Zhu J, Rodriguez-Canales J, Kawakami M, Byers LA, Woodman SE, Papadimitrakopoulou VA, Dmitrovsky E, Wang J, Ullrich SE, Wistuba II, Heymach JV, Qin FX, Gibbons DL. CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. Cancer Discov 8(9):1156-1175, 2018. e-Pub 2018. PMID: 30012853.
31. Huang L, Malu S, McKenzie JA, Andrews MC, Talukder AH, Tieu T, Karpinets T, Haymaker C, Forget MA, Williams LJ, Wang Z, Mbofung RM, Wang ZQ, Davis RE, Lo RS, Wargo JA, Davies MA, Bernatchez C, Heffernan T, Amaria RN, Korkut A, Peng W, Roszik J, Lizée G, Woodman SE, Hwu P. The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression. Clin Cancer Res 24(14):3366-3376, 2018. e-Pub 2018. PMID: 29496759.
32. Cascone T, McKenzie JA, Mbofung RM, Punt S, Wang Z, Xu C, Williams LJ, Wang Z, Bristow CA, Carugo A, Peoples MD, Li L, Karpinets T, Huang L, Malu S, Creasy C, Leahey SE, Chen J, Chen Y, Pelicano H, Bernatchez C, Gopal YNV, Heffernan TP, Hu J, Wang J, Amaria RN, Garraway LA, Huang P, Yang P, Wistuba II, Woodman SE, Roszik J, Davis RE, Davies MA, Heymach JV, Hwu P, Peng W. Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metab 27(5):977-987.e4, 2018. e-Pub 2018. PMID: 29628419.
33. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371):97-103, 2018. e-Pub 2018. PMID: 29097493.
34. Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, Babur O, Akbani R, Bristow CA, Hoadley KA, Iype L, Chang MT, Network TR, Cherniack AD, Benz C, Mills GB, Verhaak RGW, Griewank KG, Felau I, Zenklusen JC, Gershenwald JE, Schoenfield L, Lazar AJ, Abdel-Rahman MH, Roman-Roman S, Stern MH, Cebulla CM, Williams MD, Jager MJ, Coupland SE, Esmaeli B, Kandoth C, Woodman SE. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell 33(1):151, 2018. e-Pub 2018. PMID: 29316429.
35. Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol 19(2):181-193. e-Pub 2018.
36. Glitza IC, Rohlfs M, Guha-Thakurta N, Bassett RL, Bernatchez C, Diab A, Woodman SE, Yee C, Amaria RN, Patel SP, Tawbi H, Wong M, Hwu WJ, Hwu P, Heimberger A, McCutcheon IE, Papadopoulos N, Davies MA. Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open 3(1):e000283, 2018. e-Pub 2018. PMID: 29387478.
37. Oba J, Kim SH, Wang WL, Macedo MP, Carapeto F, McKean MA, Van Arnam J, Eterovic AK, Sen S, Kale CR, Yu X, Haymaker CL, Routbort M, Haydu LE, Bernatchez C, Lazar AJ, Grimm EA, Hong DS, Woodman SE. Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in KIT-Mutant Melanoma. JCO Precis Oncol 2018, 2018. e-Pub 2018. PMID: 30094412.
38. Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, Babur O, Akbani R, Bristow CA, Hoadley KA, Iype L, Chang MT, Network TR, Cherniack AD, Benz C, Mills GB, Verhaak RGW, Griewank KG, Felau I, Zenklusen JC, Gershenwald JE, Schoenfield L, Lazar AJ, Abdel-Rahman MH, Roman-Roman S, Stern MH, Cebulla CM, Williams MD, Jager MJ, Coupland SE, Esmaeli B, Kandoth C, Woodman SE. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell 32(2):204-220.e15, 2017. e-Pub 2017. PMID: 28810145.
39. Park J, Talukder AH, Lim SA, Kim K, Pan K, Melendez B, Bradley SD, Jackson KR, Khalili JS, Wang J, Creasy C, Pan BF, Woodman SE, Bernatchez C, Hawke D, Hwu P, Lee KM, Roszik J, Lizée G, Yee C. SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity. Cancer Immunol Res 5(8):618-629, 2017. e-Pub 2017.
40. Kim DW, Haydu LE, Joon AY, Bassett RL, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, Woodman SE, Roszik J, Kim KB, Gershenwald JE, Lazar AJ, Davies MA. Clinicopathological features and clinical outcomes associated with TP53 and BRAF(N)(on-)(V)(600) mutations in cutaneous melanoma patients. Cancer 123(8):1372-1381, 2017. e-Pub 2017. PMID: 27911979.
41. Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med 9(379), 2017. e-Pub 2017. PMID: 28251903.
42. Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med 2, 2017. e-Pub 2017. PMID: 28819565.
43. Johnson CP, Kim IK, Esmaeli B, Amin-Mansour A, Treacy DJ, Carter SL, Hodis E, Wagle N, Seepo S, Yu X, Lane AM, Gragoudas ES, Vazquez F, Nickerson E, Cibulskis K, McKenna A, Gabriel SB, Getz G, Van Allen EM, 't Hoen PAC, Garraway LA, Woodman SE. Systematic genomic and translational efficiency studies of uveal melanoma. PLoS One 12(6):e0178189, 2017. e-Pub 2017. PMID: 28594900.
44. Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Forget MA, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, Davies MA, Woodman SE. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med 14(1):168, 2016. e-Pub 2016. PMID: 27776519.
45. Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, Chen PL, Hwu P, Allison JP, Futreal A, Wargo JA, Sharma P. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell 167(2):397-404.e9, 2016. e-Pub 2016. PMID: 27667683.
46. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov 6(8):827-37, 2016. e-Pub 2016. PMID: 27301722.
47. Johnson DB, Roszik J, Shoushtari AN, Eroglu Z, Balko JM, Higham C, Puzanov I, Patel SP, Sosman JA, Woodman SE. Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum. Pigment Cell Melanoma Res 29(4):470-3, 2016. e-Pub 2016. PMID: 27089234.
48. Yoo JH, Shi DS, Grossmann AH, Sorensen LK, Tong Z, Mleynek TM, Rogers A, Zhu W, Richards JR, Winter JM, Zhu J, Dunn C, Bajji A, Shenderovich M, Mueller AL, Woodman SE, Harbour JW, Thomas KR, Odelberg SJ, Ostanin K, Li DY. ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma. Cancer Cell 29(6):889-904, 2016. e-Pub 2016. PMID: 27265506.
49. Ekmekcioglu S, Davies MA, Tanese K, Roszik J, Shin-Sim M, Bassett RL, Milton DR, Woodman SE, Prieto VG, Gershenwald JE, Morton DL, Hoon DS, Grimm EA. Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and its Expression Associates with Favorable Survival for Stage III Melanoma. Clin Cancer Res 22(12):3016-24, 2016. e-Pub 2016. PMID: 26783288.
50. Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology 5(3):e1136044, 2016. e-Pub 2016. PMID: 27141370.
51. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL, Bosenberg MW, Woodman SE, Overwijk WW, Lizée G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu P. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 6(2):202-16, 2016. e-Pub 2016. PMID: 26645196.
52. Roszik J, Wu CJ, Siroy AE, Lazar AJ, Davies MA, Woodman SE, Kwong LN. Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. Sci Rep 6:19649, 2016. e-Pub 2016. PMID: 26787600.
53. Wilson MA, Zhao F, Khare S, Roszik J, Woodman SE, D'Andrea K, Wubbenhorst B, Rimm DL, Kirkwood JM, Kluger HM, Schuchter LM, Lee SJ, Flaherty KT, Nathanson KL. Copy number changes are associated with response to treatment with carboplatin, paclitaxel, and sorafenib in melanoma. Clin Cancer Res 22(2):374-82, 2016. e-Pub 2016. PMID: 26307133.
54. Han L, Diao L, Yu S, Xu X, Li J, Zhang R, Yang Y, Werner HM, Eterovic AK, Yuan Y, Li J, Nair N, Minelli R, Tsang YH, Cheung LW, Jeong KJ, Roszik J, Ju Z, Woodman SE, Lu Y, Scott KL, Li JB, Mills GB, Liang H. The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. Cancer Cell 28(4):515-28, 2015. e-Pub 2015. PMID: 26439496.
55. Glitza IC, Haymaker C, Bernatchez C, Vence LM, Rohlfs ML, Richard J, Lacey C, Mansaray R, Fulbright OJ, Ramachandran R, Toth C, Wardell S, Woodman SE, Patel S, Hwu WJ, Radvanyi L, Davies MA, Papadopoulos NE, Hwu P. Intrathecal administration of tumor-infiltrating lymphocytes is well tolerated in a patient with leptomeningeal disease from metastatic melanoma: A case report. Cancer Immunol Res. e-Pub 2015. PMID: 26216417.
56. Capparelli C, Rosenbaum S, Berman-Booty LD, Salhi A, Gaborit N, Zhan T, Chervoneva I, Roszik J, Woodman SE, Davies MA, Setiady YY, Osman I, Yarden Y, Aplin AE. ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas. Cancer Res. e-Pub 2015. PMID: 26206558.
57. Woodman SE. Genomic Classification of Cutaneous Melanoma. Cell 161(7):1681-96, 2015. e-Pub 2015. PMID: 26091043.
58. Tetzlaff MT, Pattanaprichakul P, Wargo J, Fox PS, Patel KP, Estrella JS, Broaddus RR, Williams MD, Davies MA, Routbort MJ, Lazar AJ, Woodman SE, Hwu WJ, Gershenwald JE, Prieto VG, Torres-Cabala CA, Curry JL. Utility of BRAF V600E immunohistochemical expression pattern as a surrogate of BRAF mutation status in 154 patients with advanced melanoma. Hum Pathol. e-Pub 2015. PMID: 26058727.
59. Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA. Beyond BRAF(V600): Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. J Invest Dermatol 135(2):508-15, 2015. e-Pub 2015. PMID: 25148578.
60. Roszik J, Woodman SE. HotSpotter: efficient visualization of driver mutations. BMC Genomics 15(1):1044. e-Pub 2014. PMID: 25435088.
61. Alrwas A, Papadopoulos NE, Cain S, Patel SP, Kim KB, Deburr TL, Bassett R, Hwu WJ, Bedikian AY, Davies MA, Woodman SE, Hwu P. Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma. Melanoma Res 24(4):342-8, 2014. e-Pub 2014. PMID: 24743052.
62. Chattopadhyay C, Grimm EA, Woodman SE. Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration. PLoS One 9(2):e83957, 2014. e-Pub 2014. PMID: 24551032.
63. Griewank K, Westekemper H, Murali R, Mach M, Schilling B, Wiesner T, Schimming T, Livingstone E, Sucker A, Grabellus F, Metz C, Susskind D, Hillen U, Speicher MR, Woodman SE, Steuhl KP, Schadendorf D. Conjunctival Melanomas harbor BRAF and NRAS Mutations and Copy Number Changes Similar to Cutaneous and Mucosal Melanomas. Clin Cancer Res. e-Pub 2013. PMID: 23633454.
64. Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, Frederick DT, Cooper ZA, Mbofung RM, Whittington M, Flaherty KT, Woodman SE, Davies MA, Radvanyi LG, Overwijk WW, Lizée G, Hwu P. BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice. Clin Cancer Res 19(2):393-403, 2013. e-Pub 2013. PMID: 23204132.
65. Kim J, Lazar AJ, Davies MA, Homsi J, Papadopoulos NE, Hwu WJ, Bedikian AY, Woodman SE, Patel SP, Hwu P, Kim KB. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma. J Cutan Pathol 39(9):821-5, 2012. e-Pub 2012. PMID: 22809251.
66. Yang Y, Liu C, Peng W, Lizée G, Overwijk WW, Liu Y, Woodman SE, Hwu P. Anti-tumor T cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood. e-Pub 2012. PMID: 22936666.
67. Khalili JS, Yu X, Wang J, Hayes BC, Davies MA, Lizee G, Esmaeli B, Woodman SE. Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11-Dependent Manner. Clin Cancer Res. e-Pub 2012. PMID: 22733540.
68. Griewank KG, Yu X, Khalili J, Sozen MM, Stempke-Hale K, Bernatchez C, Wardell S, Bastian BC, Woodman SE. Genetic and Molecular Characterization of Uveal Melanoma Cell Lines. PIGM CELL MELANOMA R 25(2):182-7, 2012. e-Pub 2012. PMID: 22236444.
69. Deng W, Vashisht Gopal YN, Scott A, Chen G, Woodman SE, Davies MA. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. PIGM CELL MELANOMA R. e-Pub 2011. PMID: 22171948.
70. Woodman SE, Williams MD, Esmaeli B. Uveal Melanoma—Molecular Basis and Potential Treatment Targets. US Ophthalmic Review 4(2):131-5, 2011. e-Pub 2011.
71. Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, Davies MA. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 70(21):8736-47, 2010. e-Pub 2010. PMID: 20959481.
72. Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, Woodman SE, Calderone TC, Ju Z, Lazar AJ, Prieto VG, Aldape K, Mills GB, Gershenwald JE. Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res 15(24):7538-7546, 2009. e-Pub 2009. PMID: 19996208.
73. Torres-Cabala CA, Wang WL, Trent J, Yang D, Chen S, Galbincea J, Kim KB, Woodman SE, Davies M, Plaza JA, Nash JW, Prieto VG, Lazar AJ, Ivan D. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 22(11):1446-56, 2009. e-Pub 2009. PMID: 19718013.
74. Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM, Fermeglia M, Gopal YN, Yang D, Podoloff DA, Ivan D, Kim KB, Papadopoulos N, Hwu P, Mills GB, Davies MA. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 8(8):2079-85, 2009. e-Pub 2009. PMID: 19671763.
75. De Souza AP, Cohen AW, Park DS, Woodman SE, Tang B, Gutstein DE, Factor SM, Tanowitz HB, Lisanti MP, Jelicks LA. MR imaging of caveolin gene-specific alterations in right ventricular wall thickness. Magn Reson Imaging 23(1):61-8, 2005. e-Pub 2005. PMID: 15733789.
76. Woodman SE, Cheung MW, Tarr M, North AC, Schubert W, Lagaud G, Marks CB, Russell RG, Hassan GS, Factor SM, Christ GJ, Lisanti MP. Urogenital alterations in aged male caveolin-1 knockout mice. J Urol 171(2 Pt 1):950-7, 2004. e-Pub 2004. PMID: 14713860.
77. Sotgia F, Bonuccelli G, Minetti C, Woodman SE, Capozza F, Kemp RG, Scherer PE, Lisanti MP. Phosphofructokinase muscle-specific isoform requires caveolin-3 expression for plasma membrane recruitment and caveolar targeting: implications for the pathogenesis of caveolin-related muscle diseases. Am J Pathol 163(6):2619-34, 2003. e-Pub 2003. PMID: 14633633.
78. Sotgia F, Woodman SE, Bonuccelli G, Capozza F, Minetti C, Scherer PE, Lisanti MP. Phenotypic behavior of caveolin-3 R26Q, a mutant associated with hyperCKemia, distal myopathy, and rippling muscle disease. Am J Physiol Cell Physiol 285(5):C1150-60, 2003. e-Pub 2003. PMID: 12839838.
79. Bonuccelli G, Sotgia F, Schubert W, Park DS, Frank PG, Woodman SE, Insabato L, Cammer M, Minetti C, Lisanti MP. Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. Am J Pathol 163(4):1663-75, 2003. e-Pub 2003. PMID: 14507673.
80. Woodman SE, Ashton AW, Schubert W, Lee H, Williams TM, Medina FA, Wyckoff JB, Combs TP, Lisanti MP. Caveolin-1 knockout mice show an impaired angiogenic response to exogenous stimuli. Am J Pathol 162(6):2059-68, 2003. e-Pub 2003. PMID: 12759260.
81. Cohen AW, Park DS, Woodman SE, Williams TM, Chandra M, Shirani J, Pereira de Souza A, Kitsis RN, Russell RG, Weiss LM, Tang B, Jelicks LA, Factor SM, Shtutin V, Tanowitz HB, Lisanti MP. Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts. Am J Physiol Cell Physiol 284(2):C457-74, 2003. e-Pub 2003. PMID: 12388077.
82. Schubert W, Frank PG, Woodman SE, Hyogo H, Cohen DE, Chow CW, Lisanti MP. Microvascular hyperpermeability in caveolin-1 (-/-) knock-out mice. Treatment with a specific nitric-oxide synthase inhibitor, L-NAME, restores normal microvascular permeability in Cav-1 null mice. J Biol Chem 277(42):40091-8, 2002. e-Pub 2002. PMID: 12167625.
83. Woodman SE, Park DS, Cohen AW, Cheung MW, Chandra M, Shirani J, Tang B, Jelicks LA, Kitsis RN, Christ GJ, Factor SM, Tanowitz HB, Lisanti MP. Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade. J Biol Chem 277(41):38988-97, 2002. e-Pub 2002. PMID: 12138167.
84. Park DS, Woodman SE, Schubert W, Cohen AW, Frank PG, Chandra M, Shirani J, Razani B, Tang B, Jelicks LA, Factor SM, Weiss LM, Tanowitz HB, Lisanti MP. Caveolin-1/3 double-knockout mice are viable, but lack both muscle and non-muscle caveolae, and develop a severe cardiomyopathic phenotype. Am J Pathol 160(6):2207-17, 2002. e-Pub 2002. PMID: 12057923.
85. Woodman SE, Schlegel A, Cohen AW, Lisanti MP. Mutational analysis identifies a short atypical membrane attachment sequence (KYWFYR) within caveolin-1. Biochemistry 41(11):3790-5, 2002. e-Pub 2002. PMID: 11888297.
86. Lee H, Woodman SE, Engelman JA, Volonté D, Galbiati F, Kaufman HL, Lublin DM, Lisanti MP. Palmitoylation of caveolin-1 at a single site (Cys-156) controls its coupling to the c-Src tyrosine kinase: targeting of dually acylated molecules (GPI-linked, transmembrane, or cytoplasmic) to caveolae effectively uncouples c-Src and caveolin-1 (TYR-14). J Biol Chem 276(37):35150-8, 2001. e-Pub 2001. PMID: 11451957.
87. Wu DT, Woodman SE, Weiss JM, McManus CM, D'Aversa TG, Hesselgesser J, Major EO, Nath A, Berman JW. Mechanisms of leukocyte trafficking into the CNS. J Neurovirol 6 Suppl 1:S82-5, 2000. e-Pub 2000. PMID: 10871769.
88. McManus CM, Weidenheim K, Woodman SE, Nunez J, Hesselgesser J, Nath A, Berman JW. Chemokine and chemokine-receptor expression in human glial elements: induction by the HIV protein, Tat, and chemokine autoregulation. Am J Pathol 156(4):1441-53, 2000. e-Pub 2000. PMID: 10751368.
89. Woodman SE, Benveniste EN, Nath A, Berman JW. Human immunodeficiency virus type 1 TAT protein induces adhesion molecule expression in astrocytes. J Neurovirol 5(6):678-84, 1999. e-Pub 1999. PMID: 10602408.

Invited Articles

1. Jager MJ, Dogrusöz M, Woodman SE. Uveal Melanoma: Identifying Immunological and Chemotherapeutic Targets to Treat Metastases. Asia Pac J Ophthalmol (Phila) 6(2):179-185, 2017. e-Pub 2017. PMID: 28399339.
2. Woodman SE. Metastatic uveal melanoma: biology and emerging treatments. Cancer J 18(2):148-52, 2012. e-Pub 2012. PMID: 22453016.
3. Woodman SE. BAP1tism of a Tumor Suppressor. Clin Cancer Res 18(2):323-5, 2012. e-Pub 2012. PMID: 22140212.
4. Woodman SE, Lazar AJ, Aldape KD, Davies MA. New Strategies in Melanoma: Molecular Testing in Advanced Disease. Clin Cancer Res. e-Pub 2012. PMID: 22275506.
5. Patel SP, Woodman SE. Profile of ipilimumab and its role in the treatment of metastatic melanoma. DRUG DES DEV THER 5:489-95, 2011. e-Pub 2011. PMID: 22267918.
6. Woodman SE, Davies MA. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol 80(5):568-74, 2010. e-Pub 2010. PMID: 20457136.

Manuals, Teaching Aids, Other Teaching Publications

1. Woodman SE. Skin Cancer, Melanoma. In: Handbook of Targeted Cancer Therapy, 2018.
2. Woodman SE. Skin Cancer, Melanoma. In: Handbook of Targeted Cancer Therapy, 2014.

Other Articles

1. Madani M, Goldstein D, Stefanescu R, Woodman SE, Rojas-Hernandez CM Characterization of coagulopathy and outcomes in cancer patients with severe COVID -19 illness: Longitudinal changes in hospitalized cancer patients. Cancer Med 11(20):3771-3785, 2022. PMID: 35470980.
2. Oba J, Woodman SE The genetic and epigenetic basis of distinct melanoma types. J Dermatol 48(7):925-939, 2021. PMID: 34008215.
3. Chattopadhyay C, Kim DW, Gombos DS, Oba J, Qin Y, Williams MD, Esmaeli B, Grimm EA, Wargo JA, Woodman SE, Patel SP Uveal melanoma: From diagnosis to treatment and the science in between. Cancer 122(15):2299-312, 2016. PMID: 26991400.
4. Quintás-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P, Medscape Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 5(12):737-40, 2008. PMID: 18936790.
5. Woodman SE, Sotgia F, Galbiati F, Minetti C, Lisanti MP Caveolinopathies: mutations in caveolin-3 cause four distinct autosomal dominant muscle diseases. Neurology 62(4):538-43, 2004. PMID: 14981167.
6. Frank PG, Woodman SE, Park DS, Lisanti MP Caveolin, caveolae, and endothelial cell function. Arterioscler Thromb Vasc Biol 23(7):1161-8, 2003. PMID: 12689915.
7. Razani B, Woodman SE, Lisanti MP Caveolae: from cell biology to animal physiology. Pharmacol Rev 54(3):431-67, 2002. PMID: 12223531.

Editorials

1. Peng G, Woodman SE, Mills GB. RADical response puts an exceptional responder in CHKmate: a synthetic lethal curative response to DNA-damaging chemotherapy?. Cancer Discov 4(9):988-90, 2014. PMID: 25185187.
2. Woodman SE. BAP1tism of a Tumor Suppressor. Clinical Cancer Research 18((2)):325-5, 2012. PMID: 22140212.
3. Woodman SE, Mills GB. Are oncogenes sufficient to cause human cancer?. P NATL ACAD SCI USA 107(48):20599-600, 2010. PMID: 21084639.

Abstracts

1. Haifeng Z, Xiaoxing Y, Jianhua Z, Wei-Lien W, Khalida W, Creasy CA, Forget MA, Haymaker CL, Eterovic K, Mills GB, Lazar AJ, Burton EM, Morgan M, Davies MA, Wargo JA, Gershenwald JE, Bernatchez C, Futreal A, Woodman SE. Integrated Multi-Omics Integration of Patient Derived Cancer Cells Accelerated by Platform-based Analytic Engine. Presented at HealthCon in Washington, DC, March 6th, 2019, 2019. e-Pub 2019.
2. Shephard MP, Glover M, Balmes G, Cain S, Vardeleon A, Mouton R, Posada L, Simien R, Hwu P Davies M, Yee C, Wong K, Tawbi H, Woodman SE, Amaria R, Diab A, Glitza I, Hwu WJ, Patel S. Clinical characteristics of responses to nivolumab plus ipilimumab (Nivo/Ipi) in metastatic uveal melanoma. Presented at AACR Special Conference on Melanoma: From Biology to Target, Houston, TX, January 15-18, 2019, 2019. e-Pub 2019.
3. Zhu H, Orta J, Yu X, Creasy CA, Forget MA, Carapet F, Haymaker CL, Wu CJ, Karpinets TV, Wang WL, Tetzlaff MT, Lazar AJ, Mills GB, Moore AR, Chen Y, Zhang J, Gershenwald JE, Wargo JA, Bernatchez C, Hwu P, Futreal PA, Woodman SE. Nongenomic BAP1 aberrancy drives highly aggressive cutaneous melanoma phenotype. Presented at AACR Special Conference on Melanoma. Presented at AACR Special Conference on Melanoma: From Biology to Target in Houston, TX, January 15-18, 2019, 2019. e-Pub 2019.
4. Chattopadhyay C, Oba J, Roszick J, Woodman SE, Grimm EA. Elevated endogeneous SDHA drives pathologic metabolism in highly metastatic uveal melanoma. Presented at AACR Special Conference on Melanoma: From Biology to Target in Houston, TX, January 15-18, 2019, 2019. e-Pub 2019.
5. McKean MA, Oba J, Ma J, Haydu LE, Bassett Jr RL, Woodman SE. Immune checkpoint inhibitor responses in KIT-mutated metastatic melanoma. Journal of Clinical Oncology 36(5):suppl 199, 2018. e-Pub 2018.
6. Tawbi HA, Amaria RN, Glitza IC, Milton D, Hwu WJ, Patel SP, Wong MKK, Yee C, Woodman SE, Mcquade JL, Hwu P, Perdon KM, Shephard M, Burton EM, Wargo JA, Davies MA. Safety and Preliminary Activity Data From a Single Center Phase II Study of TRIplet combination of Nivolumab (N) with Dabrafenib (D) and Trametinib (T) [TRIDeNT] in Patients (Pts) with BRAF-Mutated Metastatic Melanoma (MM). Proceedings of ASCO 2018, 2018. e-Pub 2018.
7. Tawbi HA, Peng W, Milton D, Amaria RN, Glitza IC, Hwu WJ, Patel SP, Wong MKK, Woodman SE, Yee C, McQuade JL, Tetzlaff MT, Lazar AJ, Cain S, Burton EM, Beumer JH, Hwu P, Davies MA. Phase I/II Study of the PI3Kβ Inhibitor GSK2636771 in Combination with Pembrolizumab (P) in Patients (pts) with PD-1 Refractory Metastatic Melanoma (MM) and PTEN Loss. Proceedings of ASCO Annual Meeting 2018, 2018. e-Pub 2018.
8. Mitra A, Roh W, Reuben A, Macedo M, Carapeto FC, Gumbs C, Zhang J, Woodman SE, Hwu P, Hwu WJ, Lazar AJ, Wargo JA, Futreal PA. Multi-spatial whole-lesion molecular heterogeneity of an immunotherapy-resistant metastatic melanoma. Proceedings of ASCO Annual Meeting 2018, 2018. e-Pub 2018.
9. Cascone T, McKenzie JA, Mbofung R, Punt S, Wang Z, Xu C, Williams L, Wang Z, Bristow C, Carugo A, People M, Li L, Karpinets T, Malu S, Creasy C, Leahey S, Chen J, Bernatchez C, Vashisht Gopal YN, Heffernan TP, Hu J, Wang J, Amaria RN, Garraway LA, Wistuba II, Woodman SE, Roszik J, Davis RE, Davies MA, Heymach JV, Hwu P, Peng W. Functional correlation of increased tumor intrinsic glycolytic activity with resistance to adoptive T cell therapy. Journal for ImmunoTherapy of Cancer, Proceedings of SITC 2017, 2017. e-Pub 2017.
10. Andrews M, Chen WS, Spencer C, Gopalakrishnan V, Tawbi H, Lazar A, Tetzlaff M, Patel S, Hwu P, Hwu WJ, Diab A, Glitza I, AMaria R, Burton E, Woodman S, Davies M, Gershenwald J, Sharma P, Allison J, Futreal A, Wargo JA. Molecular, immune and microbial predictors of response ans toxicity to combination immune checkpoint blockade (CICB) in melanoma (MEL) patients. Proceedings of SMR 2017, 2017. e-Pub 2017.
11. Reddy S, Amaria RN, Spencer CN, Tetzlaff M, Reuben A, Andrews M, Wang L, Woodman S, Zhu H, Blando J, Vence L, Zhang S, Jiang H, Gopalakrishnan V, Hudgens C, Wani K, Tawbi H, Diab A, Glitza I, Patel S, Hwu WJ, Wong M, Hwu P, Cormier J, Lucci A, Royal R, Lee JE, Simpson L, Burton EM, Gershenwald MR, Allison J, Sharma P, Davies M, Wargo J. Neoadjuvant nivolumab versus combination ipilimumab and nivolumab followed by adjuvant nivolumab in patients with resectable state III and oligometastatic stage IV melanoma: preliminary findings. Journal for ImmunoTherapy of Cancer, Proceedings of SITC 2017:78, 2017. e-Pub 2017.
12. Johnson D, Zobniw C, Trinh V, Bassett R, Ma J, Anderson J, Davis J, Joseph J, Uemura M, Yee C, Amaria R, Patel S, Tawbi H, Glitza I, Davies M, Wong M, Woodman S, Hwu P, Hwu WJ, Wang Y, Diab A. Infliximab associated with faster symptom resolution compared to corticosteroids alone for management of immune related enterocolitis. Proceedings of SITC 2017, 2017. e-Pub 2017.
13. Haymaker C, Uemura M, Hwu WJ, Murthy R, James M, Bhatta A, Bentebibel SE, Brevard J, Geib J, Lipford K, Cornfeld M, Chunduru S, Yee C, Woodman SE Amaria R, Patel S, Tawbi H, Glitza IO, Davies M, Overwijk W, Hwu P, Bernatchez C, Diab A. TLR9 agonist harnesses innate immunity to drive tumor-infiltrating T cell expansion in distant lesions in a phase 1/2 study of intratumoral IMO-2125+ipilimumab in antiPD1 refractory melanoma patients. Journal for ImmunoTherapy of Cancer, Proceedings of SITC 2017:82, 2017. e-Pub 2017.
14. Diab A, Haymaker C, Uemura M, Murthy R, James M, Geib J, Cornfeld M, Swann S, Yee C, Wargo J, Amaria R, Patel S, Tawbi H, Glitza I, Woodman S, Hwu WJ, Davies MA, Overwijk W, Bernatchez C, Hwu P. A Phase 1/2 trial of Intrantumoral (i.t.) IMO-2125 (IMO) in combination with checkpoint inhibitors (CPI) in PD-(L)1-refractory melanoma. Annals of Oncology, Proceedings of ESMO 2017, 2017. e-Pub 2017.
15. Park J, Talukder AH, Lim SA, Kim K, Pan K, Melendez B, Bradley SD, Jackson KR, Khalili JS, Wang J, Creasy C, Pan BF, Woodman SE, Bernatchez C, Hawke D, Hwu P, Lee KM, Roszik J, Lizee G, Yee C. SLC45A2: A melanoma antigen with high tumor selectivity and reduced potential for autoimmune toxicity. Cancer Immunol Res, Proceedings of AACR 2017 5(8):618-629, 2017. e-Pub 2017.
16. Chen WS, Andrews MC, Spencer C, Tawbi HAH, Lazar A, Tetzlaff MT, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Amaria RN, Burton EM, Woodman SE, Davies MA, Gershenwald JE, Sharma P, Allison JP, Futreal A, Wargo JA. Molecular and immune predictors of response and toxicity to combined CTLA-4 and PD-1 blockade in metastatic melanoma (MM) patients (pts). ASCO Annual Meeting 2017, 2017. e-Pub 2017.
17. Wargo JA, Amaria RN, Prieto PA, Andrews MC, Tetzlaff MT, Futreal PA, Hwu P, Hwu WJ, Glitza IC, Tawbi HAH, Cormier JN, Lee JE, Patel SP, Simpson L, Burton EM, Jr BR, Ross MI, Gershenwald JE, Davies MA, Woodman SE. Treatment with neoadjuvant and adjuvant dabrafenib + trametinib (D+T) compared to standard-of-care (SOC) surgery and to identify targets to enhance responses in patients (pts) with high-risk resectable BRAF-mutant metastatic melanoma. Proceedings of ASCO Annual Meeting 2017, 2017. e-Pub 2017.
18. Chattopadhyay C, Roszik J, Grimm E, Woodman SE. Monosomy 3 uveal melanoma cells have a unique metabolic phenotype distinct from disomy 3. Investigative Ophthalmology & Visual Science, Proceedings of ARVO 2017 58(8), 2017. e-Pub 2017.
19. Royal R, Vence L, Wray T, Cormier J, Lee J, Gershenwald J, Ross M, Wargo J, Amaria R, Davies MA, Diab A, Glitza IC, Hwu WJ, Patel S, Woodman S, Overwijk W, Hwu P. A toll-like receptor agonist to drive melanoma regression as vaccination adjuvant or by direct tumor application. Proceedings of ASCO 2017, 2017. e-Pub 2017.
20. Yang H, Tan S, Grossniklaus HE, Morales VM, Zhang Q, Burgess BL, Hu DN, Woodman SE, McCannel TA, Yang J. CXCR4 expression in an intraocular melanoma mouse model with hepatic metastases. Investigative Ophthalmology & Visual Science, Proceedings of ARVO 2017 58(8), 2017. e-Pub 2017.
21. Keung E, Burton E, Amaria R, Glitza IC, Patel S, Diab A, Yee C, Wong M, Hwu WJ, Hwu P, Woodman S Tetzlaff M, Milton D, Perez K, Davies M, Rai K, Wargo J, Tawbi H. A toll-like receptor agonist to drive melanoma regression as vaccination adjuvant or by direct tumor application. Proceedings of ASCO 2017, 2017. e-Pub 2017.
22. Davies MA, Joon A, Bassett RL, Roszik J, Siroy A, Haydu LE, Chen K, Stingo F, Baladandayuthapani V, Shaw KR, Bernstam FM, Tetzlaff MT, Gershenwald JE, Woodman SE, Lazar AJF. Demographics, Tumor Characteristics, and Clinical Outcomes Associated with Somatic Mutations in 201 Cancer-related Genes in Advanced Melanoma Patients (pts). Journal of Clinical Oncology, Proceedings of ASCO Annual Meeting 2015 33(15), 2017. e-Pub 2017.
23. Dumbrava EE, Brusco L, Daniels MS, Wathoo C, Shaw KR, Lu KH, Zheng X, Strong LC, Litton JK, Arun B, Eterovic AK, Piha-Paul SA, Subbiah V, Hong DS, Woodman SE, Mendelsohn J, Yap TA, Mills GB, Chen K, Meric-Bernstam F. Pathogenic Variants in DNA Damage Response (DDR) Genes in Patients with Advanced Solid Tumors. Journal of Clinical Oncology, Proceedings of ASCO Annual Meeting 2017 35(no 15 suppl), 2017. e-Pub 2017.
24. Haymaker C, Uemura M, Murthy R, James M, Wang D, Brevard J, Swann S, Geib J, Cornfeld M, Chundura S, Agrawal S, Yee C, Wargo J, Amaria R, Patel S, Tawbi H, Glitza I, Woodman S, Hwu WJ, Davies MA, Hwu P, Overwijk W, Bernatchez C, Diab A. Translational evidence of reactivated innate and adaptive immunity with intratumoral IMO-2125 in combination with systemic checkpoint inhibitors from a Phase I/II study in patients with anti-PD-1 refractory metastatic melanoma. Cancer Research, Proceedings of AACR 2017 58, 2017. e-Pub 2017.
25. Wargo JA, Amaria RN, Prieto PA, Andrews MC, Tetzlaff MT, Futrea PA, Hwu P, Hwu WJ, Glitza IC, Tawbi HA, Cormier JN, Lee JE, Patel SP, Simpson LE, Burton EM, Bassett RL, Ross MI, Gershenwald JE, Davies MA, Woodman SE. Relapse-free Survial and Target Identification to Enhance Response with Neoadjuvant and Adjuvant Dabrafenib + Trametinib (D+T) Treatment Compared to Standard-of-Care (SOC) Surgery in Patients (pts) with High-Risk Resectable BRAF-Mutant Metastatic Melanoma. Journal of Clinical Oncology, Proceedings of ASCO Annual Meeting 2017 35(15_suppl), 2017. e-Pub 2017.
26. Chattopadhyay C, Woodman SE. Monosomy 3 uveal melanoma cells have a unique metabolic phenotype distinct from disomy 3, 2017. e-Pub 2017.
27. Keung E, Burton EM, Amaria RN, Glitza IC, Patel SP, Diab A, Yee C, Wong MK, Hwu WJ, Hwu P, Woodman SE, Tetzlaff MT, Milton D, Perez K, Davies MA, Rai K, Wargo JA, Tawbi HA. A Phase II Study of Oral Azacitidine (CC-486) in Combination with Pembrolizumab (PEMBRO) in Patients with Metastatic Melanoma (MM). Journal of Clinical Oncology (Proceedings of ASCO Annual Meeting 2017) 35(15):suppl 9594, 2017. e-Pub 2017.
28. Lundqvist A, Hoef VV, Zhang X, Wennerberg E, Woodman SE, Hwu WJ, Davies MA, Hwu P, Valsesia-Wittmann S, Shekarian T, Simard F, Nailo R, Dutour A, Jallas AC, Caux C, Marabelle. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer. Proceddings of SITC 2016 Annual Meeting, 2016. e-Pub 2016.
29. Amaria, RN, Prieto P, Tetzlaff M, Diab A, Patel S, Woodman SE, Hwu WJ, Glitza IC, Hwu P, Tawbi H, McQuade JL, Cormier J, Lucci A, Royal R, Lee J, Bassett R, Simpson L, Burton EM, Grimm EA, Reuben A, Spencer C, Gershenwald JE, Ross M, Davies MA, Wargo JA. Treatment with neoadjuvant + adjuvant dabrafenib and trametinib (D+T) is associated with imporoved relapse-free survival (RFS versus standard of care (SOC) therapy in ptients with high-risk resectable BRAF-mutant melanoma. Proceedings of SMR Congress 2016, 2016. e-Pub 2016.
30. Zezhong HY, Zhang Q, Craven CM, Woodman SE, McCannel TA, Grossniklaus HE. Loss of BAP1 results in high metastatic rate in a mouse ocular melanoma model. Investigative Ophthalmology & Visual Science, Proceedings of ARVO 2016 57(12), 2016. e-Pub 2016.
31. Ekmekcioglu S, Davies MA, Tanese K, Roszik J, Shin-Sim M, Bassett RL, Milton DR, Woodman SE, Prieto VG, Gershenwald JE, Morton DL, Hoon DS, Grimm EA. Inflammatory marker testing identifies CD74 expression in melanoma tumor cells, and its expression associates with favorable survival for stage III melanoma. Clin Cancer Res, Proceedings of 2016 22(12):3016-3024, 2016. e-Pub 2016.
32. Amaria RN, Haymaker CL, Bernatchez C, Forget MA, Patel V, Hwu WJ, Davies MA, Patel SP, Diab A, Glitza IC, Tawbi HAH, Woodman SE, Wargo JA, Ross MI, Lee JE, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Hwu P. A phase I/II study of lymphodepletion plus adoptive cell transfer (ACT) with T cells transduced with CXCR2 and NGFR followed by high dose interleukin-2 (IL-2) in patients with metastatic melanoma (MM). Proceedings ASCO Annual Meeting 2016, 2016. e-Pub 2016.
33. Reuben A, Spencer CN, Prieto PA, Miller JP, Mao X, Chen WS, Cheung H, Jiang H, Haymaker C, Petaccia M, Garber HR, Chen PL, Gopalakrishnan V, Austin-Breneman J, Hudgens CW, Roszik J, Hwu P, Woodman SE, Chin L, Davies MA, Amaria RN, Patel SP, Lazar AJ, Tetzlaff MT, Dwyer KC, Wistuba II, Sharma P, Allison JP, Zhang J, Futreal A, Cooper ZA, Wargo JA. Genomic and Immune Heterogeneity in Synchronous Melanoma Metastases is Associated with Differential Tumor Growth and Response to Therapy. Cancer Res, Proceedings of AACR 107th Annual Meeting 2016 76(14):2392, 2016. e-Pub 2016.
34. Kim DW, Haydu LE, Joon A, Bassett RL, Siroy A, Tetzlaff MT, Lazar A, Woodman SE, Gershenwald JE, Davies MA. Pathological and clinical features of non-acral cutaneous melanoma (CM) patients (pts) with TP53 and BRAFnon-V600 (NonV600) mutations (muts). Proceedings of ASCO 2016 34(no. 15_suppl):9535-9535, 2016. e-Pub 2016.
35. Yang H, Li Z, Zhang Q, Craven CM, Woodman SE, McCannel TA, Grossniklaus HE. Loss of BAP1 Results in High Metastatic Rate in a Mouse Ocular Melanoma Model. Investigative Ophthalmology & Visual Science, Proceedings of ARVO Annual Meeting 2016 57(12), 2016. e-Pub 2016.
36. Karpinets T, Calderone T, Wani K, Yu X, Creasy C, Haymaker C, Forget M, Nanda V, Roszik J, Wargo J, Haydu L, Song X, Lazar A, Gershenwald J, Davies M, Bernatchez C, Zhang J, Futreal A, Woodman SE. Melanoma Reprogramming State Correlates with Response to CTLA-4 Blockade in Metastatic Melanoma. Hum Genomic, Presented at Human Genome Meeting 2016(10, Suppl 1), 2016. e-Pub 2016.
37. Chen PL, Roh W, Reuben A, Spencer CN, Jiang H, Lazar A, Davies MA, Miller JP, Wani K, Hwu P, Patel SP, Woodman SE, Glitza IC, HWJ, Cooper ZA, Allison J, Sharma, P Wistuba I, Blando J, Prieto V, Tetzlaff M, Amaria RN, Futreal A, Chin L, Wargo JA. ImmuneInfiltrate in Early On-Treatment Biopsies is Highly Predictive of Response to Immune Checkpoint Blockade. Pigment Cell & Melanoma Research 28(6):763, 2015. e-Pub 2015.
38. Austin-Breneman JL, Reuben A, Spencer CN, Roszik J, Miller JP, Kwong L, Jiang H, Roh W, Cao Y, Little LD, Amaria RN, Garber HR, Gopalakrishnan V, Chen PL, Haymaker C, Forget MA, Davies M, Bernatchez C, Tetzlaff M, Woodman SE, Dwyer KC, Chin L, Futreal A, Cooper ZA, Wargo JA. Immune and Molecular Heterogeneity in Synchronous Melanoma Metastases. Pigment Cell & Melanoma Research 28((6)):755, 2015. e-Pub 2015.
39. Reuben A, Spencer C, Jason R, Miller J, Kwong L, Jiang H, Haymaker C, Chen PL, Austin-Breneman J, Roh W, Little L, Cao Y, Garber H, Forget MA, Gopalakrishnan V, Amaria R, Davies ME, Bernatchez C, Roger E, Cuentas P, Rodriguez J, Tetzlaff M, Woodman SE, Dwyer K, Sharma P, Allison J, Chin L, Futreal A, Cooper Z, Wargo J. Molecular and Immune Heterogeneity in Synchronous Melanoma Metastases. Journal for ImmunoTherapy of Cancer, Proceedings of Society for Immunotherapy of Cancer 2015 20153(Suppl2):P262, 2015. e-Pub 2015.
40. Glitza IC, Rohlfs M, Bassett R, John I, Richard J, Iqbal M, Bernzen T, Gerber D, Lacey C, Diab A, Amaria R, Woodman SE, Patel SP, Yee C, Hwu WJ, McCutcheon IE, Heimberger A, Hwu P, Papadopoulos NE, Davies MA. IMCT-07 Therapeutic Outcomes of Intrathecal Interleukin-2 in Metastatic Melanoma Patients with Leptomeningeal Disease (LMD). NeuroOncology, Proceedings of the Society for Neuro-Oncology Meeting 2015 17(suppl_5, 1):v108, 2015. e-Pub 2015.
41. Glitza IC, Rohlfs ML, Bassett R, John I, Richard J, Iqbal M, Bernzen T, Gerber DL, Lacey C, Diab A, Amaria RM, Woodman SE, Patel SP, YeeCC, Hwu WJ, Hwu P, Papadopoulos N, Davies MA. Long-term Efficacy of Intrathecal Interleukin-2 (IT IL2) in Metastatic Melanoma (MM) Patients (pts) with Leptomeningeal Disease (LMD). Journal European, Journal of Cancer, Proceedings of European Cancer Congress 2015 51(S109), 2015. e-Pub 2015.
42. Oba J, Wang WL, Eterovic AK, Stephan CC, Roszik J, Kale CR, Haymaker CL, Routbort M, Haydu LE, Bernatchez CE, Davies MA, Lazar AJF, Grimm EA, Woodman SE. Global Genomic and Small Molecule Inhibitor Interrogation of KIT Mutant Melanoma Reveals Underlying Biology and Implicates Novel Molecular Targets. Journal of Clinical Oncology, Proceedings of ASCO Annual Meeting 2015:9039, 2015. e-Pub 2015.
43. Johnson CP, Kim IK, Esmaeli B, Amin-Mansour, Treacy DJ, Carter SL, Hodis E, Wagle N, Seepo S, Yu X, Vasquez F, Nickerson E, Cibulskis K, McKenna A, Gabriel SB, Getz G, Van Allen EM, Garraway LA, Woodman SE. Systematic Genomic Characterization of Uveal Melanoma. Cancer Research, Proceedings of AACR Special Conference:Translation of the Cancer Genome 2015 22(Suppl1:A1-15), 2015. e-Pub 2015.
44. Kim IK, Place CS, Esmaeli B, Amin-Mansour, Treacy D, Carter S, Hodis E, Wagle N, Seepo S, Vasquez F, Nickerson E, Cibulskis K, McKenna A, Gabriel SB, Getz G, Van Allen EM, Garraway LA, Woodman SE. Systematic genomic characterization of primary and metastatic uveal melanoma, 2015. e-Pub 2015.
45. Roth KG, Siroy AE, Tetzlaff M, Roszik J, Meric-Bernstam F, Shaw KR, Mills GB, Routbort M, Hess KR, Haydu LE, Gershenwald J, Lazar A, Davies M, Woodman SE. Mutation and Clinical Analysis of a Large Cohort of Acral and Mucosal Melanomas, 2015. e-Pub 2015.
46. Tetzlaff M, Pattanaprichakul P, Wargo J, Fox P, Patel K, Estrella J, Broaddus R, Davies ME, Routbort M, Lazar A, Prieto V, Hwu WJ, Gershenwald J, Woodman SE, Torres-Cabala C, Curry J. Utility of BRAFV600E Immunohistochemistry (IHC) Expression Pattern as a Surrogate of BRAFV600 Mutation Status in 154 Patients with Advanced Stage Melanoma. In Laboratory Investigation 95:126A, 2015. e-Pub 2015.
47. Amaria RN, Bassett RL, Simpson L, Delaney F, Hwu P, Kim K, Hwu WJ, Patel SP, Glitza IC, Davies MA, Woodman SE, Yee C, Bedikian AY. Phase I study of ipilimumab (IPI) with biochemotherapy (BCT) for chemonaïve patients with metastatic melanoma (MM). Proceedings ASCO Annual Meeting, 2015. e-Pub 2015.
48. Davies MA, Joon A, Bassett RL, Roszik J, Siroy A, Haydu LE, Chen K, Stingo F, Baladandayuthapani V, Shaw KR, Meric-Bernstam F, Tetzlaff MT, Gershenwald JE, Woodman SE, Lazar AJF. Demographics, tumor characteristics, and clinical outcomes associated with somatic mutations in 201 cancer-related genes in advanced melanoma patients (pts). Proceedings of ASCO Annual Meeting 2015, 2015. e-Pub 2015.
49. Kemnade J, Roszik J, Joon A, Stingo F, Baladandayuthapani V, Lazar AJF, Woodman SE, Davies MA. Identification of potentially actionable mutations in RTKs in melanoma detected by next generation sequencing (NGS). Proceedings ASCO Annual Meeting 2015, 2015. e-Pub 2015.
50. Kim DW, Haymaker C, Perdon K, Amaria R, Mcquail N, Fa'ak F, Spencer CN, Sirmans E, Glitza I, Wargo JA, Woodman S, Patel S, Davies M, Hwu W, Bernatchez C, Hwu P, Diab A. Phase II trial of nab-paclitaxel (ABI) plus ipilimumab (ipi) in patients with metastatic melanoma (MM). Proceedings of SMR 2015, 2015. e-Pub 2015.
51. Kim IK, Place CS, Esmaeli B, Amin-Mansour, Lane AM, Gragoudas ES, Van Allen EM, Garraway LA, Woodman SE. Exome sequencing of primary and metastatic uveal melanoma. Proceedings of Retinal Society Annual Meeting, 2015, 2015. e-Pub 2015.
52. Kim DW, Haymaker C, McQuail N, Sirmans E, Spencer C, Glitza I, Amaria R, Woodman S, Patel S, Davies M, Yee C, Hwu WJ, Bernatchez C, Wargo J, Sharma P, Allison J, Hwu P, Tam A, Diab A. Phase II trial of nab-paclitaxel (ABI) plus ipilimumab (ipi) in patients with metastatic melanoma. Journal for Immunotherapy of Cancer, Proceedings of SITC 2015, 2015. e-Pub 2015.
53. De Macedo MP, Reuben A, Qin Y, Reddy S, Spencer CN, Jiang H, Bernatchez C, Austin-breneman JL, Gopalakrishnan V, Guindani M, Gombos D, Esmaeli B, Grimm EA, Chattopadhyay C, Oba J, Woodman SE, Hwu P, Williams M, Tetzlaff M, Cooper ZA, Wargo JA, Lazar A, Patel S. Understanding the Determinants of Resistance to Therapy in Metastatic Uveal Melanoma. Pigment Cell & Melanoma Research, Proceedings of Society for Melanoma Research Congress 2015 28(6):806, 2015. e-Pub 2015.
54. Kim DW, Haymaker C, Mcquail N, Sirmans E, Spencer C, Glitza I, Amaria R, Woodman S, Patel S, Davies M, Yee C, Hwu WJ, Bernatchez C, Wargo J, Sharma P, Allison J, Hwu P, Tam A, Diab A. Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM). Journal of Immunotherapy of Cancer, Proceedings of SITC 2015, 2015. e-Pub 2015.
55. Roszik J, Joon A, Siroy A, Haydu L, Stingo F, Baladandayuthapani V, Hwu P, Tetzlaff M, Wargo J, Chen JQ, Radvanyi L, Bernatchez C, Gershenwald J, Lazar AJ, Davies MA, SE <. A Novel Algorithm Applicable to Cancer Next Generation Sequencing Panels Accurately Predicts Total Tumor Mutation Load and Correlates with Clinical Outcomes in Melanoma. Journal of Clinical Oncology, Proceeding of ASCO Annual Meeting 2015 33(15_suppl), 2015. e-Pub 2015.
56. Kim D, Kim K, Papadopoulos N, Bedikian AB, Hwu WJ, Frankian S, Siroy A, Routbort M, Haydu L, Lazar A, Diab A, Amaria RN, Woodman SE, Patel SP, Hwu P, Davies M. Pathological and Clinical Characteristics ofTP53 Mutations in Patients with Melanoma. Pigment Cell & Melanoma Research 27(6):1202-1203, 2014. e-Pub 2014.
57. Joon L, Haydu V, Baladandayuthapani, Stingo F, Woodman SE, Amaria RN, Wargo JA, Shaw KR, Meric-Bernstam F, Mills GB, Gershenwald JE, Hwu P, Lazar A, Davies ME. Next Generation Sequencing of 201 Cancer Related genes in Melanoma. Pigment Cell & Melanoma Research 27(6):1184, 2014. e-Pub 2014.
58. Wong F, Chen SY, Woodman SE, Kim KB. Early Metabolic Responses on FDG PET-CT in 7 Days Correlate with Progression-free Survival (PFS) in Patients with Metastatic Melanomas after Initiation of Targeted Therapy. J Nucl Med 55(suppl 1):653, 2014. e-Pub 2014.
59. Kim DW, Nowroozi S, Kim K, Davies MA, Routbort M, Lazar AJF, Frankian S, Siroy A, Bedikian AY, Papadopoulos NE, Hwu WJ, Hwu P, Woodman SE, Patel SP, Kim KB. Clinical Characteristics of Patients with non-V600 BRAF Mutant Melanomas. Journal of Clinical Oncology 32(15_suppl):9100, 2014. e-Pub 2014.
60. Siroy AE, Prieto VG, Gershenwald JE, Woodman SE, Roszik J, Aldape KD, Luthra R, Patel KP, Routbort MJ, Davies MA, Lazar AJ. Clinical Next-Generation Sequencing Reveals Divergent Mutational Patterns in BRAF V600, BRAF Non-V600, and NRAS Mutations in Advanced Melanoma. In Laboratory Investigation 94:143A, 2014. e-Pub 2014.
61. Amaria RN, Bassett RL, Simpson L, Delaney F, Hwu P, Kim KB, Hwu WJ, Patel SP, Glitza IC, Davies MA, Woodman SE, Yee C, Bedikian AY. Phase I Study of Ipilimumab (IPI) with Biochemotherapy (BCT) for Chemonaïve Patients with Metastatic Melanoma (MM). Journal of Clinical Oncology 33(no. 15_suppl e20014), 2014. e-Pub 2014.
62. Glitza IC, Bernatchez C, Bassett RL, Vaughn C, Velasquez P, Diab A, Amaria RN, Yee C, Woodman SE, Patel SP, Kim KB, Davies MA, Papadopoulos NE, Bedikian AY, Hwu WJ, Radvanyi LG, Hwu P. Treatment with tumor-infiltrating lymphocytes (TIL) in metastatic melanoma and clinical benefit regardless of site of origin, mutation status, or prior checkpoint blockade. Proceedings ASCO Annual Meeting 2014, 2014. e-Pub 2014.
63. Chattopadhyay C, Grimm E, Woodman SE. Simultaneous Inhibition of the HGF/MET and Erk1/2 Pathways Affect Uveal Melanoma Cell Growth Migration. Investigative Ophthalmogy & Visual Science, Proceedings of ARVO 2013 54(15):4211, 2013. e-Pub 2013.
64. Nowroozi S, Zuo Z, Patel K, Patel SP, Luthra R, Routbort M, Alexander JF, Lazar, Davies MA, Hasanein H, Papadopoulos NE, Hwu WJ, Bedikian AY, Woodman SE, Hwu P, Kim KB. Clinical Characteristics of Melanoma Patients with non-V600E/K BRAF Mutations. Journal of Clinical Oncology 31(15_suppl), 2013. e-Pub 2013.
65. Griewank KG, Westekemper H, Schilling B, Mach M, Murali R, Wiesner T, Schimming T, Grabellus F, Metz C, Sucker A, Hillen U, Speicher M, Woodman SE, Steuhl K, Schadendorf D. Oncogene and Copy Number Analysis of a Larger Cohort of Conjunctival Melanoma. Experimental Dermatology 22(3), 2013. e-Pub 2013.
66. Alrwas A, Alvarado G, Bernatchez C, Wei C, Radvanyi L, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Papadopoulos NE, Kim KB, Bedikian AY, Hwu WJ, Patel SP, Woodman SE, Davies ME, Ross MI, Lee J, Gershenwald J, Cormier J, Lucci A, Royal R, Hwu P. Tumor-infiltrating Lymphocyte (til) Growth as a Prognostic Factor in Patients (pts) with Metastatic Melanoma (mm). Pigment Cell & Melanoma Research 26(6):934, 2013. e-Pub 2013.
67. Bedikian AY, Kim KB, Papadopoulos NE, Hwu W, Patel SP, Davies MA, Mahoney S, Hwu P, Woodman SE. Phase I/II Study of LOC-paclitaxel (LOC-Pac) in Patients (pts) with Metastatic Melanoma. Journal of Clinical Oncology 30(15_suppl), 2012. e-Pub 2012.
68. Alrwas A, Papadopoulos NE, Cain S, Patel SP, Kim KB, Deburr TL, Bassett R, Hwu W, Bedikian AY, Davies MA, Woodman SE, Hwu P. Phase I study of Nab-paclitaxel (NP) in Combination with Biochemotherapy (BCT) in Patients (pts) with Metastatic Melanoma (MM). Journal of Clinical Oncology 30(15_suppl), 2012. e-Pub 2012.
69. Chattopadhyay C, Woodman SE, Esmaeli B, Grimm EA. Targeting IGF-1R In Uveal Melanoma Cells. Proceedings of ARVO Annual Meeting, 2012 53((14)):3396, 2012. e-Pub 2012.
70. Yang Y, Liu C, Peng W, Mbofung RN, Lizee G, Overwijk WW, Woodman SE, Hwu P. The Anti-tumor T Cell Response Plays a Critical Role in the Therapeutic Effect of Dasatinib on C-kit Mutant Mastocytoma and can be Potentiated by Anti-OX40 Antibody. Journal of Immunotherapy 35(9):775, 2012. e-Pub 2012.
71. Woodman SE, Yu X, Chattopadhyay C, Williams M, Poindexter N, Jager MJ, Grimm E, Esmaeli B. GNAQ/11 Mutant Dependent Uveal Melanoma Sensitivity to MEK and PI3K Inhibitors. International Society of Ocular Oncology International Meeting, 2011. e-Pub 2011.
72. Woodman SE, Yu X, Chattopadhyay C, Poindexter N, Grimm E. GNAQ/11 Mutant Dependent Uveal Melanoma Sensitivity to MEK and PI3K Inhibitors. National Cancer Institute Translational Science Meeting, 2011. e-Pub 2011.
73. Woodman SE, Yu X, Chattopadhyay C, Williams M, Poindexter N, Jager MJ, Grimm E, Esmaeli B. GNAQ/11 Mutant Dependent Uveal Melanoma Sensitivity to MEK and PI3K Inhibitors. Association for Research in Vision and Ophthalmology Annual Meeting, 2011. e-Pub 2011.
74. Patel SP, Bedikian AY, Papadopoulos NE, Hwu W, Kim KB, Homsi J, Davies MA, Woodman SE, Radvanyi LG, Woodard K, Mahoney S, Hwu P. Ipilimumab Plus Temozolomide in Metastatic Melanoma. Journal of Clinical Oncology 29(15_suppl):8579, 2011. e-Pub 2011.
75. Dorkhom SJ, Kim J, Lazar AJF, Davies MA, Homsi J, Papadopoulos NE, Hwu W, Bedikian AY, Woodman SE, Patel SP, Hwu P, Kim KB. BRAF, NRAS, and KIT Mutational Analysis of Spindle Cell Melanoma. Journal of Clinical Oncology 29(15_suppl), 2011. e-Pub 2011.
76. Chattopadhyay C, Woodman SE, Esmaeli B, Grimm EA. Targeting c-Met/HGF Pathway in Uveal Melanoma Cells. Investigative Ophthalmology & Visual Science, Proceedings of ARVO 2012 52:1443, 2011. e-Pub 2011.
77. Woodman SE, Trent JC, Stemke-Hale K, Lazar A, Pricl S, Pavan GM, Papadopoulos N, Hwu P, Mills GB, Davies MA. Selective Activity of Dasatinib for the Most Common KIT Mutation in Melanoma (L576P). Journal of Clinical Oncology, Proceedings of ASCO Annual Meeting 2009 15(suppl), 2009. e-Pub 2009.
78. Sotgia F, Woodman SE, Bonuccelli G, Capozza F, Minetti C, Scherer PE, Lisanti MP. MUSCLE CELL BIOLOGY AND CELL MOTILITY-Phenotypic Behavior of Caveolin-3 R26Q, a Mutant Associated with HyperCKemia, Distal Myopathy, and Rippling Muscle Disease. American Journal of Physiology-Cell Physiology 54(5):C1150, 2003. e-Pub 2003.

Book Chapters

1. Margolin K, Sondak V, Swetter S, Woodman SE. In: Melanoma In: Holland-Frei Cancer. 9th. John Wiley & Sons, 2017.
2. Woodman SE. KIT Kinase. In: Targeted Therapy in Translational Cancer Research. John Wiley & Sons, Inc, 2016.
3. Woodman SE. Handbook of Targeted Cancer Therapy. In: Handbook of Targeted Cancer Therapy.

Letters to the Editor

1. Yu X, Ambrosini G, Roszik J, Eterovic AK, Stempke-Hale K, Seftor EA, Chattopadhyay C, Grimm E, Carvajal RD, Hendrix MJ, Hodi FS, Schwartz GK, Woodman SE. Genetic Analysis of the 'Uveal Melanoma' C918 Cell Line Reveals Atypical BRAF and Common KRAS Mutations and Single Tandem Repeat Profile Identical to the Cutaneous Melanoma C8161 Cell Line. Pigment Cell Melanoma Res 28: 357-9, 2015.